AI-Discovered Lung Disease Drug Enters Phase III Trials in China
96Stats · x · 2026-07-14
A lung disease drug entirely discovered by AI has officially entered Phase III clinical trials in China.\n\nReports indicate that AI handled the entire R&D process for this drug, from identifying disease targets to designing the drug molecules. Currently, 320 名患者 are participating in the trial to verify its actual efficacy, which has shown positive therapeutic potential in earlier stages.
Related event: AI-Discovered Drug Enters Phase III Trials in China(2 posts)→
More from Research
- Deep Learning Course Adds Mechanistic Interpretability Lecture This Winter — CSProfKGD · 2026-10-26
- INCLUDE-2.0 benchmark evaluates regional knowledge across 91 languages and 86 countries — ABosselut · 2026-10-26
- CoRL paper: flow-matching VLAs can run 1-step Euler inference with no retraining — kaixhin · 2026-10-26
- CoVer at EMNLP 2026: Training Code LLMs to Generate and Self-Verify Simultaneously — algo_diver · 2026-10-26
- Robotic dexterity should be judged on speed, force control and tool use, not copying humans — DJiafei · 2026-10-26
- Turing-complete malware can run in PyTorch's backward pass via a zero-valued loss — retr0jirachi · 2026-10-26